Germany OKs Dutch on-line drug sales

15 January 2001

The District Court of Berlin, Germany, has given the Dutch Internetpharmacy company Doc Morris permission to sell pharmaceuticals over the Internet, according to the Europe Intelligence Wire. The decision was based on a European Union regulation, the wire service noted, adding that because a Frankfurt court had granted a temporary injunction last November, the legal basis for the on-line sale of medicine was unclear.

Doc Morris had offered German medical insurance companies an average 20% discount on medicines, and the suit had been brought by the German federation for social competition, the VSW, which represents the pharmaceutical industry. A spokesman for the group said it would appeal the decision.

Doc Morris offers about 1,000 prescription and over-the-counter drugs on the Internet at discount prices in several EU countries. Unlike some other websites, it requires a prescription before medications which need one can be delivered.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight